These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21216303)

  • 1. Family friction as ΔNp73 antagonises p73 and p53.
    Bailey SG; Cragg MS; Townsend PA
    Int J Biochem Cell Biol; 2011 Apr; 43(4):482-6. PubMed ID: 21216303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
    Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
    J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
    Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
    Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting p73--a potential approach in cancer treatment.
    Slade N; Horvat A
    Curr Pharm Des; 2011; 17(6):591-602. PubMed ID: 21391909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
    Vilgelm A; El-Rifai W; Zaika A
    Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative expression of TAp73 and ΔNp73 isoforms.
    Conforti F; Yang AL; Agostini M; Rufini A; Tucci P; Nicklison-Chirou MV; Grespi F; Velletri T; Knight RA; Melino G; Sayan BS
    Aging (Albany NY); 2012 Mar; 4(3):202-5. PubMed ID: 22388545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.
    Hassan HM; Dave BJ; Singh RK
    Curr Mol Med; 2014 May; 14(4):432-9. PubMed ID: 24730526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells.
    Nakagawa T; Takahashi M; Ozaki T; Watanabe K; Hayashi S; Hosoda M; Todo S; Nakagawara A
    Cancer Lett; 2003 Jul; 197(1-2):105-9. PubMed ID: 12880968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-specific expression of p73 C-terminal isoforms in mice.
    Grespi F; Amelio I; Tucci P; Annicchiarico-Petruzzelli M; Melino G
    Cell Cycle; 2012 Dec; 11(23):4474-83. PubMed ID: 23159862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
    Muttray AF; Cox RL; Reinisch CL; Baldwin SA
    Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
    Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
    Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.
    Petrenko O; Zaika A; Moll UM
    Mol Cell Biol; 2003 Aug; 23(16):5540-55. PubMed ID: 12897129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
    Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
    Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of p73 activity by post-translational modifications.
    Conforti F; Sayan AE; Sreekumar R; Sayan BS
    Cell Death Dis; 2012 Mar; 3(3):e285. PubMed ID: 22419114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncoprotein E7 from beta human papillomavirus 38 induces formation of an inhibitory complex for a subset of p53-regulated promoters.
    Saidj D; Cros MP; Hernandez-Vargas H; Guarino F; Sylla BS; Tommasino M; Accardi R
    J Virol; 2013 Nov; 87(22):12139-50. PubMed ID: 24006445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functions, divergence and clinical value of TAp73 isoforms in cancer.
    Logotheti S; Pavlopoulou A; Galtsidis S; Vojtesek B; Zoumpourlis V
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):511-34. PubMed ID: 23592418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p63 and p73: roles in development and tumor formation.
    Moll UM; Slade N
    Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
    Zhang L; Nie L; Maki CG
    Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and apoptotic function of p73.
    Yoon MK; Ha JH; Lee MS; Chi SW
    BMB Rep; 2015 Feb; 48(2):81-90. PubMed ID: 25441426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.